The Political Gabfest discusses the Mylan controversy and why the EpiPen costs so much.

Is It Really OK to Shame Mylan for the EpiPen’s Skyrocketing Prices?

Is It Really OK to Shame Mylan for the EpiPen’s Skyrocketing Prices?

Slate Plus
Your all-access pass
Sept. 2 2016 1:46 PM
Comments

When Is It OK to Shame a Whole Company?

The Political Gabfest asks why the EpiPen costs so much.

Lunceford Stevens holds an EpiPen during a protest outside the offices of hedge fund manager John Paulson over his fund's investment in Mylan, which manufactures EpiPens, in New York City, U.S., August 30, 2016.
How should medicines such as the EpiPen be priced?

Brendan McDermid/Reuters

For Friday’s edition of the Political Gabfest Slate Plus bonus segment, hosts Emily Bazelon, John Dickerson, and David Plotz discuss the recent controversies surrounding Mylan, a drug company, and its decision to substantially raise the price of the EpiPen. When is it OK to shame a whole company? How should drug prices be regulated? And should schools be required to stock these extremely expensive EpiPens at the cost of other resources?

You can subscribe to this and other Slate Plus podcasts on our podcast subscription page.